These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 19935387)
21. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353 [TBL] [Abstract][Full Text] [Related]
22. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K; Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462 [TBL] [Abstract][Full Text] [Related]
23. Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study. Mavroudis D; Pavlakou G; Blazoyiannakis G; Veslemes M; Apostolopoulou F; Kouroussis Ch; Kakolyris S; Agelaki S; Androulakis N; Vardakis N; Magkanas E; Samonis G; Georgoulias V Lung Cancer; 2003 Jan; 39(1):71-6. PubMed ID: 12499097 [TBL] [Abstract][Full Text] [Related]
24. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer. Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862 [TBL] [Abstract][Full Text] [Related]
25. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Kirschling RJ; Grill JP; Marks RS; Kugler JW; Gerstner JB; Kuross SA; Michalak JC; Windschitl HE; Krewer KD; Jett JR Am J Clin Oncol; 1999 Oct; 22(5):517-22. PubMed ID: 10521070 [TBL] [Abstract][Full Text] [Related]
26. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. Park SH; Cho EK; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Lee JI; Choi SJ; Park J; Shin DB; Lee JH Cancer Chemother Pharmacol; 2008 Nov; 62(6):1009-14. PubMed ID: 18259751 [TBL] [Abstract][Full Text] [Related]
27. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. Frasci G; Nicolella G; Comella P; Carreca I; DeCataldis G; Muci D; Brunetti C; Natale M; Piantedosi F; Russo A; Palmeri S; Comella G; Panza N Br J Cancer; 2001 May; 84(9):1166-71. PubMed ID: 11336465 [TBL] [Abstract][Full Text] [Related]
28. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U J Natl Cancer Inst; 2003 Aug; 95(15):1118-27. PubMed ID: 12902441 [TBL] [Abstract][Full Text] [Related]
29. Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide. Miller AA; Niell HB Lung Cancer; 2001; 33(2-3):241-8. PubMed ID: 11551419 [TBL] [Abstract][Full Text] [Related]
30. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma. Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768 [TBL] [Abstract][Full Text] [Related]
31. Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer. Pujol JL; von Pawel J; Tumolo S; Martoni A; Hearn S; Fields SZ; Ross G Oncology; 2001; 61 Suppl 1():47-54. PubMed ID: 11598415 [TBL] [Abstract][Full Text] [Related]
32. Long-term survival in SCLC after treatment with paclitaxel, carboplatin and etoposide--a phase II study. Reck M; Jagos U; Grunwald F; Kaukel E; Koschel G; von Pawel J; Hessler S; Gatzemeier U Lung Cancer; 2003 Jan; 39(1):63-9. PubMed ID: 12499096 [TBL] [Abstract][Full Text] [Related]
33. A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC). Patel SH; Ajlouni M; Chapman R; Lu M; Movsas B; Kim JH J Thorac Oncol; 2007 Sep; 2(9):831-7. PubMed ID: 17805061 [TBL] [Abstract][Full Text] [Related]
34. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L; Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097 [TBL] [Abstract][Full Text] [Related]
35. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C; Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454 [TBL] [Abstract][Full Text] [Related]
36. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study. Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535 [TBL] [Abstract][Full Text] [Related]
37. Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer. Zarogoulidis K; Mylonaki E; Kakavelas P; Zarogoulidis P; Tsiouda T; Rapti E; Lithoxopoulou H; Zarogoulidou V; Kontakiotis T; Lung Cancer; 2009 Nov; 66(2):226-30. PubMed ID: 19321222 [TBL] [Abstract][Full Text] [Related]
38. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Spigel DR; Hainsworth JD; Simons L; Meng C; Burris HA; Yardley DA; Grapski R; Schreeder M; Mallidi PV; Greco FA; J Thorac Oncol; 2007 Sep; 2(9):854-61. PubMed ID: 17805064 [TBL] [Abstract][Full Text] [Related]
39. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study. Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952 [TBL] [Abstract][Full Text] [Related]
40. Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer. Seifart U; Fink T; Schade-Brittinger C; Hans K; Mueller C; Koschel G; Schroeder H; Lorenz R; Dethling J; Wolf M Ann Oncol; 2007 Jan; 18(1):104-109. PubMed ID: 17071939 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]